The PrE0505 phase 2 clinical trial results are published in the November 8 issue of Nature Medicine. The study evaluated the addition of durvalumab immunotherapy to standard chemotherapy in patients with previously untreated, inoperable malignant pleural mesothelioma (MPM), a cancer of the tissues that line the lungs. The trial met its…
Immunotherapy prolongs survival in recurrent, persistent or metastatic cervical cancer
The addition of immunotherapy to standard first-line treatment extends survival by eight months for patients with recurrent, persistent or metastatic cervical cancer, according to late breaking results from the KEYNOTE-826 study presented at the ESMO Congress 2021. Cervical cancer is a global problem, with more than 600,000 new cases and…
Combination immunotherapy for advanced bowel cancer approved for NHS in England
People who have previously been treated for a type of bowel cancer that has spread to other parts of their body will now have another treatment option in England, following the approval of the combined use of nivolumab (Opdivo) and ipilimumab (Yervoy) for these patients. The National Institute of Health…
Cancer immunotherapy may also treat certain autoimmune diseases
A team of researchers has found disrupting the interaction between cancer cells and certain immune cells is more effective at killing cancer cells than current immunotherapy treatments. The findings, which include studies in cell lines and animal models, appeared in JCI Insight and focus on a protein called CD6 as…
UTHSC professor awarded $1.79 million grant to develop new amyloidosis treatment
The National Institute of Diabetes and Digestive and Kidney Diseases recently awarded Jonathan Wall, PhD, professor in the University of Tennessee Health Science Center's Graduate School of Medicine in Knoxville, a $1.79 million grant for his study titled "Developing a Theranostic Immunotherapy for Systemic Amyloidosis." Amyloidosis is a rare disease…
UTHSC professor awarded $1.79 million grant to develop new amyloidosis treatment
The National Institute of Diabetes and Digestive and Kidney Diseases recently awarded Jonathan Wall, PhD, professor in the University of Tennessee Health Science Center's Graduate School of Medicine in Knoxville, a $1.79 million grant for his study titled "Developing a Theranostic Immunotherapy for Systemic Amyloidosis." Amyloidosis is a rare disease…
Immune cells in cerebrospinal fluid could be novel biomarkers to immune-based therapies
Results from a study led by Joan Seoane, Director of Preclinical and Translational Research co-program at VHIO and ICREA Professor, show that immune cells accessing cerebrospinal fluid faithfully recapitulate the characteristics of cells identified in brain metastasis, and could therefore constitute novel biomarkers of response to immune-based therapies. Immune checkpoint…
Researchers develop mutant gene-targeted immunotherapy approach to fight cancers
A novel targeted immunotherapy approach developed by researchers at the Ludwig Center, the Lustgarten Laboratory, and Bloomberg~Kimmel Institute for Cancer Immunotherapy at the Johns Hopkins Kimmel Cancer Center employs new antibodies against genetically altered proteins to target cancers. The researchers targeted their immunotherapy approach to alterations in the common cancer-related…
Researchers develop mutant gene-targeted immunotherapy approach to fight cancers
A novel targeted immunotherapy approach developed by researchers at the Ludwig Center, the Lustgarten Laboratory, and Bloomberg~Kimmel Institute for Cancer Immunotherapy at the Johns Hopkins Kimmel Cancer Center employs new antibodies against genetically altered proteins to target cancers. The researchers targeted their immunotherapy approach to alterations in the common cancer-related…
Immunotherapy side effect could be a positive sign for kidney cancer patients
An autoimmune side effect of immune checkpoint inhibitor (ICI) drugs could signal improved control of kidney cancer, according to a new study by researchers in UT Southwestern’s Kidney Cancer Program (KCP). The study, published today in the Journal for ImmunoTherapy of Cancer, may have broad implications for patients being treated…